Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C

Journal of Hepatology

Volumn 33, Issue 1, 2000, Pages 135-141

  Guilera, Magda ^a   Forns, Xavier ^a   Torras, Xavier ^c   Enríquez, Jaime ^c   Coll, Susana ^d   Solà, Ricard ^d   Morillas, Rosa ^e   Planas, Ramón ^e   Ampurdanès, Sergi ^a   Soler, Marta ^a   Costa, Josep ^b   Sáiz, Juan C ^a   Sánchez Tapias, José M ^a,f   Rodés, Juan ^a  

^a Institut de Malalties Digestives   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e Hospital Germans Trias   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

Author keywords

Combined therapy; Corticosteroids; HCV; Prednisone; Sequential therapy; Steroid therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; PREDNISOLONE; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033917918     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80170-1     Document Type: Article

References (28)

1. Lindsay KL. Therapy of hepatitis C: overview. Hepatology. 26:1997;71-77S.
2. Farrell GC, Bacon BR, Goldin RD. Lymphoblastoid interferon alpha n-1 improves the long term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alpha-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology. 27:1998;1121-1127.
3. Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keefe EB, et al. Therapy of hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology. 26:1997;747-754.
4. Zarski JP, Maynard-Muet M, Chousterman S, Baud M, Barnoud R, Abergel A, et al. Tenoxicam, a non-steroidal anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon. Hepatology. 27:1998;862-867.
5. Boucher E, Jouanolle H, André P, Ruffault A, Guyader D, Moirand R, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral hepatitis: results from a controlled randomized trial in 80 patients. Hepatology. 21:1995;322-327.
6. Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Randomised, double blind, placebo controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet. 351:1998;83-87.
7. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
8. McHutchison JG, Gordon SC, Schiff ER, Shiftman ML, Lee WM, Rutsgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 339:1998;1485-1492.
9. Pawlotsky JM. Hepatitis C virus infection: virus/host interactions. J Viral Hepat. 5:(Suppl 1):1998;3-8.
10. Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, et al. Ribavirin polarizes human T cell response towards a Type 1 cytokine profile. J Hepatol. 30:1999;376-382.
11. Rakela J, Redeker AG, Weliky B. Effect of short-term prednisone therapy on aminotransferase levels and hepatitis B virus markers in chronic type B hepatitis. Gastroenterology. 84:1983;956-960.
12. Fong TL, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology. 107:1994;196-199.
13. Cohard M, Poynard T, Mathurin P, Zarski JP. Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metaanalysis. Hepatology. 20:1994;1390-1398.
14. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC, Lindsay K, Payne J, et al. A randomized controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med. 323:1990;295-302.
15. Krogsgaard K, Marcellin P, Trepo C, Berthelot P, Sánchez-Tapias JM, Bassendine M, et al. Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. J Hepatol. 25:1996;803-813.
16. Liaw YF, Sheen IS, Lin SM, Chen TJ, Chu CM. Effects of prednisolone pretreatment in interferon alfa therapy for patients with chronic non-A, non-B hepatitis. Liver. 13:1993;46-50.
17. Chayama K, Tsubota A, Kobayashi M, Hashimoto M, Miyano Y, Koike M, et al. A pilot study of corticosteroid priming for lymphoblastoid interferon alfa in patients with chronic hepatitis C. Hepatology. 23:1996;953-957.
18. Olmedo E, Costa J, López-Labrador FX, Forns X, Ampurdanés S, Maluenda MD, et al. Comparative study of a modified competitive RT-PCR and amplicor HCV monitor assays for quantitation of hepatitis C virus RNA in serum. J Med Virol. 58:1999;35-43.
19. López-Labrador F, Ampurdanés S, Forns X, Castells A, Sáiz JC, Costa J, et al. Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. J Hepatol. 27:1997;959-965.
20. Bonkovsky HL. Therapy of hepatitis C: other options. Hepatology. 26:(Suppl 1):1997;143-151S.
21. Cramp ME, Carucci P, Rossol S, Chokshi S, Maertens G, Williams R, et al. Hepatitis C virus (HCV) immune response in anti-HCV positive patients without hepatitis C viraemia. Gut. 44:1999;424-429.
22. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo CK. Detection of Type 2-like T-helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity. Hepatology. 25:1997;449-458.
23. Lasarte JJ, García-Granero M, López A, Casares N, García N, Civeira MP, et al. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology. 28:1999;815-822.
24. Orito E, Mizokami M, Suzuki K, Ohba K, Ohno T, Mori M, et al. Loss of serum HCV-RNA at week 4 of alpha interferon therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol. 46:1995;109-115.
25. Ampurdanés S, Olmedo E, Maluenda MD, Forns X, Lopez-Labrador FX, Costa J, et al. Permanent response to alpha interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. J Hepatol. 25:1996;827-832.
26. Gavier B, Martínez-González MA, Riezu-Boj JI, Lasarte JJ, García N, Civeira MP, et al. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology. 113:1997;1647-1653.
27. Bellobuono A, Mondazzi L, Tempini S, Chiodo F, Magliano E, Mondini C, et al. Should patients with early loss of serum HCV-RNA during alpha interferon therapy for chronic hepatitis C be treated for 6 or 12 months? J Hepatol. 30:1999;8-13.
28. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy in chronic hepatitis C. Hepatology. 26:(Suppl 1):1997;122-127S.